Seek and destroy: improving PK/PD profiles of anticancer agents with nanoparticles

References

• Ledford H. Cocktails for cancer with a measure of immunotherapy. Nat News. 2016;532:162.
   PubMedGoogle Scholar
• Jodrell DI, Egorin MJ, Canetta RM, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol. 1992 Apr;10(4):520–528.
   PubMed Web of Science ®Google Scholar
• Paoletti X, Ezzalfani M, Le Tourneau C. Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials. Ann Oncol Off J Eur Soc Med Oncol. 2015;26:1808–1812.
   PubMed Web of Science ®Google Scholar
• Benzekry S, Pasquier E, Barbolosi D, et al. Metronomic reloaded: theoretical models bringing chemotherapy into the era of precision medicine. Semin Cancer Biol. 2015;35:53–61.
   PubMed Web of Science ®Google Scholar
• Grenon NN, Chan J. Managing toxicities associated with colorectal cancer chemotherapy and targeted therapy. Clin J Oncol Nurs. 2009;13:285–296.
   PubMed Web of Science ®Google Scholar
• Bregoli L, Movia D, Gavigan-Imedio JD, et al. Nanomedicine applied to translational oncology: A future perspective on cancer treatment. nanomedicine nanotechnol. Biol Med. 2016;12:81–103.
   Google Scholar
• Hare JI, Lammers T, Ashford MB, et al. Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev [Internet]. [cited 2016 Sep 20]. Available from: http://www.sciencedirect.com/science/article/pii/S0169409X16301351.
   Web of Science ®Google Scholar
• Etheridge ML, Campbell SA, Erdman AG, et al. THE BIG PICTURE ON SMALL MEDICINE: THE STATE OF NANOMEDICINE PRODUCTS APPROVED FOR USE OR IN CLINICAL TRIALS. Nanomedicine nanotechnol. Biol Med. 2013;9:1–14.
   Google Scholar
• Babu A, Templeton AK, Munshi A, et al. Nanodrug delivery systems: a promising technology for detection, diagnosis, and treatment of cancer. AAPS PharmSciTech. 2014;15:709–721.
   PubMed Web of Science ®Google Scholar
• Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev. 2008;60:876–885.
   PubMed Web of Science ®Google Scholar
• Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13:238–252.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4:145–160.
   PubMed Web of Science ®Google Scholar
• Prabhu RH, Patravale VB, Joshi MD. Polymeric nanoparticles for targeted treatment in oncology: current insights [Internet]. Int J Nanomedicine. 2015 [cited 2018 Feb 7]. Available from: https://www.dovepress.com/polymeric-nanoparticles-for-targeted-treatment-in-oncology-current-ins-peer-reviewed-fulltext-article-IJN
   PubMed Web of Science ®Google Scholar
• Kataoka K, Matsumoto T, Yokoyama M, et al. Doxorubicin-loaded poly(ethylene glycol)-poly(beta-benzyl-L-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. J Control Release Off J Control Release Soc. 2000;64:143–153.
   PubMed Web of Science ®Google Scholar
• Jokerst JV, Lobovkina T, Zare RN, et al. Nanoparticle PEGylation for imaging and therapy. Nanomed. 2011;6:715–728.
   PubMed Web of Science ®Google Scholar
• Gaudin A, Song E, King AR, et al. PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma. Biomaterials. 2016;105:136–144.
   PubMed Web of Science ®Google Scholar
• Park JW, Benz CC, Martin FJ. Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol. 2004;31:196–205.
   PubMed Web of Science ®Google Scholar
• Diamantis N, Banerji U. Antibody-drug conjugates–an emerging class of cancer treatment. Br J Cancer. 2016;114:362–367.
   PubMed Web of Science ®Google Scholar
• Fanciullino R, Ciccolini J, Milano G. Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: A focus on nano-albumin-bound drugs. Crit Rev Oncol Hematol. 2013;88:504–513.
   PubMed Web of Science ®Google Scholar
• Ait-Oudhia S, Mager DE, Straubinger RM. Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology. Pharmaceutics. 2014;6:137–174.
   PubMedGoogle Scholar
• Zamboni WC. Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res. 2005;11:8230–8234.
   PubMed Web of Science ®Google Scholar
• Mori A, Klibanov AL, Torchilin VP, et al. Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. FEBS Lett. 1991;284:263–266.
   PubMed Web of Science ®Google Scholar
• Drummond DC, Meyer O, Hong K, et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51:691–744.
   PubMed Web of Science ®Google Scholar
• Levchenko TS, Rammohan R, Lukyanov AN, et al. Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int J Pharm. 2002;240:95–102.
   PubMed Web of Science ®Google Scholar
• Allen TM, Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta BBA Biomembr. 1991;1068:133–141.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen J, Cheng Y, et al. A lyophilized sterically stabilized liposome-containing docetaxel: in vitro and in vivo evaluation. J Liposome Res. 2016:1–10.
   Web of Science ®Google Scholar
• Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;54:987–992.
   PubMed Web of Science ®Google Scholar
• Fanciullino R, Mollard S, Giacometti S, et al. In vitro and in vivo evaluation of lipofufol, a new triple stealth liposomal formulation of modulated 5-Fu: impact on efficacy and toxicity. Pharm Res. 2013;30:1281–1290.
   PubMed Web of Science ®Google Scholar
• Udofot O, Affram K, Smith T, et al. Pharmacokinetic, biodistribution and therapeutic efficacy of 5-fluorouracil-loaded pH-sensitive PEGylated liposomal nanoparticles in HCT-116 tumor bearing mouse. J Nat Sci [Internet]. 2016;2. cited 2016 Sep 20. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869888/
   Google Scholar
• Kai MP, Keeler AW, Perry JL, et al. Evaluation of drug loading, pharmacokinetic behavior, and toxicity of a cisplatin-containing hydrogel nanoparticle. J Control Release Off J Control Release Soc. 2015;204:70–77.
   PubMed Web of Science ®Google Scholar
• Anwar M, Akhter S, Mallick N, et al. Enhanced anti-tumor efficacy of paclitaxel with PEGylated lipidic nanocapsules in presence of curcumin and poloxamer: in vitro and in vivo studies. Pharmacol Res. 2016;113(Part A):146–165.
   PubMedGoogle Scholar
• Ren G, Liu D, Guo W, et al. Docetaxel prodrug liposomes for tumor therapy: characterization, in vitro and in vivo evaluation. Drug Deliv. 2016;23:1272–1281.
   PubMed Web of Science ®Google Scholar
• Silverman JA, Deitcher SR. Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol. 2013;71:555–564.
   PubMed Web of Science ®Google Scholar
• Sethi VS, Jackson DV, White DR, et al. Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Res. 1981;41:3551–3555.
   PubMed Web of Science ®Google Scholar
• Drummond DC, Noble CO, Guo Z, et al. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 2006;66:3271–3277.
   PubMed Web of Science ®Google Scholar
• Chang TC, Shiah HS, Yang CH, et al. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. Cancer Chemother Pharmacol. 2015;75:579–586.
   PubMed Web of Science ®Google Scholar
• Bornmann C, Graeser R, Esser N, et al. A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging. Cancer Chemother Pharmacol. 2008;61:395–405.
   PubMed Web of Science ®Google Scholar
• Tardi P, Johnstone S, Harasym N, et al. In vivo maintenance of synergistic cytarabine: daunorubicinratios greatly enhances therapeutic efficacy. Leuk Res. 2009;33:129–139.
   PubMed Web of Science ®Google Scholar
• Nikanjam M, Capparelli EV, Lancet JE, et al. Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment. Cancer Chemother Pharmacol. 2018;81:171–178.
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Kojima H, Yamamoto H, et al. Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats. J Controlled Release. 2001;75:83–91.
   PubMed Web of Science ®Google Scholar
• Phuphanich S, Maria B, Braeckman R, et al. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt®) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J Neurooncol. 2006;81:201–208.
   PubMed Web of Science ®Google Scholar
• Chen N, Li Y, Ye Y, et al. Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel. J Clin Pharmacol. 2014;54:1097–1107.
   PubMed Web of Science ®Google Scholar
• Gardner ER, Dahut WL, Scripture CD, et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:4200–4205.
   PubMed Web of Science ®Google Scholar
• Hedrich WD, Fandy TE, Ashour HM, et al. Antibody–drug Conjugates: pharmacokinetic/pharmacodynamic modeling, preclinical characterization, clinical studies, and lessons learned. Clin Pharmacokinet. 2017 Nov 29. doi: 10.1007/s40262-017-0619-0 [Epub ahead of print].
   PubMedGoogle Scholar
• Lu D, Girish S, Gao Y, et al. Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. Cancer Chemother Pharmacol. 2014;74:399–410.
   PubMed Web of Science ®Google Scholar
• Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41:189–207.
   PubMedGoogle Scholar
• Sawant RR, Torchilin VP. Challenges in development of targeted liposomal therapeutics. Aaps J. 2012;14:303–315.
   PubMed Web of Science ®Google Scholar
• Ngoune R, Peters A, von Elverfeldt D, et al. Accumulating nanoparticles by EPR: A route of no return. J Controlled Release. 2016;238:58–70.
   PubMed Web of Science ®Google Scholar
• Fanciullino R, Mollard S, Correard F, et al. Biodistribution, tumor uptake and efficacy of 5-FU-loaded liposomes: why size matters. Pharm Res. 2014;31:2677–2684.
   PubMed Web of Science ®Google Scholar
• Heist RS, Duda DG, Sahani DV, et al. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proc Natl Acad Sci U S A. 2015;112:1547–1552.
   PubMed Web of Science ®Google Scholar
• Preclinical development: tissue distribution of doxorubicin (DOX) and TLC D-99 and conventional doxorubicin,” Data from the Registration dossier.
   Google Scholar
• Gabizon A, Isacson R, Libson E, et al. Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol Stockh Swed. 1994;33:779–786.
   PubMed Web of Science ®Google Scholar
• Webb MS, Logan P, Kanter PM, et al. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother Pharmacol. 1998;42:461–470.
   PubMed Web of Science ®Google Scholar
• Shan S, Flowers C, Peltz CD, et al. Preferential extravasation and accumulation of liposomal vincristine in tumor comparing to normal tissue enhances antitumor activity. Cancer Chemother Pharmacol. 2006;58:245–255.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Yang N, Zhang H, et al. Enhanced in vivo antitumor efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumor targeting and Hsp90 inhibition. J Controlled Release. 2016;221:26–36.
   PubMed Web of Science ®Google Scholar
• Liang Z, Yang N, Jiang Y, et al. Targeting docetaxel-PLA nanoparticles simultaneously inhibit tumor growth and liver metastases of small cell lung cancer. Int J Pharm. 2015;494:337–345.
   PubMed Web of Science ®Google Scholar
• Xu J, Gattacceca F, Amiji M. Biodistribution and pharmacokinetics of egfr-targeted thiolated gelatin nanoparticles following systemic administration in pancreatic tumor-bearing mice. Mol Pharm. 2013;10:2031–2044.
   PubMed Web of Science ®Google Scholar
• Deshpande PP, Biswas S, Torchilin VP. Current trends in the use of liposomes for tumor targeting. Nanomed. [Internet]. 2013 [cited 2016 Sep 20];8. Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842602/
   Google Scholar
• Sobot D, Mura S, Yesylevskyy SO, et al. Conjugation of squalene to gemcitabine as unique approach exploiting endogenous lipoproteins for drug delivery. Nat Commun. 2017;8:15678.
   PubMed Web of Science ®Google Scholar
• Desai NP, Trieu V, Hwang LY, et al. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer. Drugs. 2008;19:899–909.
   PubMed Web of Science ®Google Scholar
• Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006;12:1317–1324.
   PubMed Web of Science ®Google Scholar
• Desai N, Trieu V, Damascelli B, et al. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol. 2009;2(2):59–64.
   PubMed Web of Science ®Google Scholar
• Wang L, Li M, Zhang N. Folate-targeted docetaxel-lipid-based-nanosuspensions for active-targeted cancer therapy. Int J Nanomedicine. 2012;7:3281–3294.
   PubMed Web of Science ®Google Scholar
• Meissner JM, Toporkiewicz M, Czogalla A, et al. Novel antisense therapeutics delivery systems: in vitro and in vivo studies of liposomes targeted with anti-CD20 antibody. J Controlled Release. 2015;220(Part A):515–528.
   PubMedGoogle Scholar
• Yang T, Choi M-K, Cui F-D, et al. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Controlled Release. 2007;120:169–177.
   PubMed Web of Science ®Google Scholar
• Laginha KM, Moase EH, Yu N, et al. Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer. J Drug Target. 2008;16:605–610.
   PubMed Web of Science ®Google Scholar
• Shmeeda H, Tzemach D, Mak L, et al. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage. J Control Release Off J Control Release Soc. 2009;136:155–160.
   PubMed Web of Science ®Google Scholar
• Zahmatkeshan M, Gheybi F, Rezayat SM, et al. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2016;86:125–135.
   PubMed Web of Science ®Google Scholar
• Erickson HK, Phillips GDL, Leipold DD, et al. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther. 2012;11:1133–1142.
   PubMed Web of Science ®Google Scholar
• O’Brien MER, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYXTM/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440–449.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Schiller G, Lister J, et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult philadelphia chromosome–negative acute lymphoblastic leukemia. J Clin Oncol. 2013;31:676–683.
   PubMed Web of Science ®Google Scholar
• Poon KA, Flagella K, Beyer J, et al. Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability. Toxicol Appl Pharmacol. 2013;273(2):298–313.
   Google Scholar
• Poon KA, Flagella K, Beyer J, et al. Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability. Toxicol Appl Pharmacol. 2013;273:298–313.
   PubMed Web of Science ®Google Scholar
• Tijink BM, Buter J, de Bree R, et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12:6064–6072.
   PubMed Web of Science ®Google Scholar
• Krop IE, LoRusso P, Miller KD, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:3234–3241.
   PubMed Web of Science ®Google Scholar
• Launay M, Dahan L, Duval M, et al. Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer. Br J Clin Pharmacol. 2016;81:124–130.
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A, Li C-P, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet Lond. Engl. 2016;387:545–557.
   PubMed Web of Science ®Google Scholar
• Palomaki GE, Bradley LA, Douglas MP, et al. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med Off J Am Coll Med Genet. 2009;11:21–34.
   PubMed Web of Science ®Google Scholar
• Fanciullino R, Giacometti S, Mercier C, et al. In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation. Br J Cancer. 2007;97:919–926.
   PubMed Web of Science ®Google Scholar
• Couvreur P, Stella B, Reddy LH, et al. Squalenoyl nanomedicines as potential therapeutics. Nano Lett. 2006;6:2544–2548.
   PubMed Web of Science ®Google Scholar
• Cosco D, Paolino D, Cilurzo F, et al. Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases. Int J Pharm. 2012;422:229–237.
   PubMed Web of Science ®Google Scholar
• Hann B, Peth K, Wang D, et al. Lipidic nanoparticle CPT-11 in a bioluminescent orthotopic pancreas cancer model. American Association of Cancer Research Annual Meeting (abstract 5648). Philadelphia, PA, USA; 2007.
   Google Scholar
• Ko AH, Tempero MA, Shan Y-S, et al. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer. 2013;109:920–925.
   PubMed Web of Science ®Google Scholar
• LoRusso P, Krop I, Miller K, et al. Abstract CT234: A phase I study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2+ metastatic breast cancer. Cancer Res. 75(15 Supplement):CT234 AACR. Annual Meeting 2015 Philadelphia PA.
   Google Scholar
• Press Release: https://www.reuters.com/article/idUSASC09OJ3.
   Google Scholar
• Song G, Petschauer J, Madden A, et al. Nanoparticles and the mononuclear phagocyte system: pharmacokinetics and applications for inflammatory diseases. Curr Rheumatol Rev. 2014;10:22–34.
   PubMedGoogle Scholar
• Schell RF, Sidone BJ, Caron WP, et al. Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents. nanomedicine nanotechnol. Biol Med [Internet]. 2014;10. cited 2016 Sep 16. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877184/
   Google Scholar
• Tsuchihashi M, Harashima H, Kiwada H. Development of a pharmacokinetic/pharmacodynamic (PK/PD)-simulation system for doxorubicin in long circulating liposomes in mice using peritoneal P388. J Controlled Release. 1999;61:9–19.
   PubMed Web of Science ®Google Scholar
• Harashima H, Iida S, Urakami Y, et al. Optimization of antitumor effect of liposomally encapsulated doxorubicin based on simulations by pharmacokinetic/pharmacodynamic modeling. J Controlled Release. 1999;61:93–106.
   PubMed Web of Science ®Google Scholar
• Harashima H, Tsuchihashi M, Iida S, et al. Pharmacokinetic/pharmacodynamic modeling of antitumor agents encapsulated into liposomes. Adv Drug Deliv Rev. 1999;40:39–61.
   PubMed Web of Science ®Google Scholar
• El-Kareh AW, Secomb TW. A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells. Neoplasia N. Y. N. 2000;2:325–338.
   PubMed Web of Science ®Google Scholar
• Arnold RD, Mager DE, Slack JE, et al. Effect of repetitive administration of doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11:8856–8865.
   PubMed Web of Science ®Google Scholar
• Ait-Oudhia S, Straubinger RM, Mager DE. Systems pharmacological analysis of paclitaxel-mediated tumor priming that enhances nanocarrier deposition and efficacy. J Pharmacol Exp Ther. 2013;344:103–112.
   PubMed Web of Science ®Google Scholar
• Ait-Oudhia S, Straubinger RM, Mager DE. Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia. Pharm Res. 2012;29:2833–2844.
   PubMed Web of Science ®Google Scholar
• Sadekar S, Figueroa I, Tabrizi M. Antibody drug conjugates: application of quantitative pharmacology in modality design and target selection. Aaps J. 2015;17:828–836.
   PubMed Web of Science ®Google Scholar
• Betts AM, Haddish-Berhane N, Tolsma J, et al. Preclinical to clinical translation of antibody-drug conjugates using PK/PD Modeling: a retrospective analysis of inotuzumab ozogamicin. Aaps J. 2016;18:1101–1116.
   PubMed Web of Science ®Google Scholar